The developer had advanced an oncology asset to Phase II clinical results. The asset had been developed in combination with a separate development-stage product owned by a third party.
While the asset demonstrated strong potential, development challenges emerged:
Leveraged deep experience in investment and funding to evaluate the asset’s development trajectory from an investor perspective.
Redefined the TPP for commercial relevance, aligning it with global investor expectations and US market potential.
Explored the creation of a US-based Newco to orchestrate development, positioning the asset more strategically for US entry.
Based on refined insights, reshaped the CDP to optimize value creation trajectory and de-risking profile.
With Treehill Partners’ involvement:
Treehill Partners successfully transformed a regionally-developed oncology asset into a globally investable opportunity with strong prospects for U.S. commercialization.
Leveraged deep experience in investment and funding to evaluate the asset’s development trajectory from an investor perspective.
Redefined the TPP for commercial relevance, aligning it with global investor expectations and US market potential.
Redefined the TPP for commercial relevance, aligning it with global investor expectations and US market potential.
Redefined the TPP for commercial relevance, aligning it with global investor expectations and US market potential.
Leveraged deep experience in investment and funding to evaluate the asset’s development trajectory from an investor perspective.
Redefined the TPP for commercial relevance, aligning it with global investor expectations and US market potential.
Explored the creation of a US-based Newco to orchestrate development, positioning the asset more strategically for US entry.
Based on refined insights, reshaped the CDP to optimize value creation trajectory and de-risking profile.
